Your session is about to expire
← Back to Search
GnRH for Kallmann Syndrome
Study Summary
This trial is testing whether kisspeptin can help diagnose which children with delayed puberty will eventually enter puberty on their own, and which children have a permanent condition.
- Kallmann Syndrome
- Gonadotropin-Releasing Hormone Deficiency
- Delayed Puberty
- Hypogonadotropic Hypogonadism
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2009 Phase 2 trial • 36 Patients • NCT00586898Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- This study is not open to teenage boys.You have not experienced any breast development changes in the past 6 months and are in the early stages of puberty.The study does not allow participation of teenage girls.You are between 13.5 and 17 years old.Your bones are not as developed as they should be for your age.You are between the ages of 12 and 17.
- Group 1: Kisspeptin, GnRH
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the uppermost participation limit for this experiment?
"Affirmative, the clinical trial website presents information that this research is presently recruiting participants. This study was first advertised on November 1st 2011 and has been modified recently on June 29th 2022. The investigators have scheduled to accept 60 test subjects from a single medical facility."
Can I be considered as a participant in this experiment?
"Sixty participants aged between 12 and 17 who are experiencing a delay in puberty will be accepted into this medical trial. To qualify, adolescent girls must have Tanner stage I or II breast development with no changes for the past 6 months; boys should weigh more than 28kg and present a bone age less than their chronological age."
Has research been conducted with the hormone GnRH before?
"Presently, 46 trials exploring GnRH are underway. 10 of these being in the later stages (Phase 3). Although most research on this hormone is based out of Chicago Illinois, 1321 other locations host studies for this therapy."
Are there any potential hazards associated with GnRH administration?
"Our team has assigned GnRH a score of 1 due to lack of evidence for the drug's efficacy and safety, as it is only in its first stage of clinical trials."
Is the recruiting process for this research experiment currently underway?
"Yes, there is evidence on clinicaltrials.gov that this medical trial is actively recruiting participants. Initially posted in November 2011 and last edited June 2022, the study seeks to enrol 60 patients at a single location."
Is this medical study open to minors?
"As stated in the inclusion criteria, only minors between 12 and 17 years of age can join this clinical trial."
Who else is applying?
What state do they live in?
How old are they?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger